Stocks and Investing
Stocks and Investing
Wed, February 23, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Robert Burns Maintained (BNTX) at Strong Buy with Decreased Target to $339 on, Feb 23rd, 2022
Robert Burns of HC Wainwright & Co., Maintained "BioNTech SE" (BNTX) at Strong Buy with Decreased Target from $366 to $339 on, Feb 23rd, 2022.
Robert has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, all agree with Robert's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $217 on, Tuesday, February 1st, 2022
- Simon Baker of "Redburn Partners" Upgraded from Strong Sell to Hold on, Tuesday, February 1st, 2022
- Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $225 on, Tuesday, November 9th, 2021
Contributing Sources